Avenzo Therapeutics, Inc.
🇺🇸United States
Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid TumorHR+/HER2- Breast CancerHR+, HER2-, Advanced Breast CancerCDK Gene MutationCCND1 Gene AmplificationCDK4 Gene Amplification
- Interventions
- First Posted Date
- 2025-05-31
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Avenzo Therapeutics, Inc.
- Target Recruit Count
- 380
- Registration Number
- NCT06998407
- Locations
- 🇺🇸
Avenzo Therapeutics Recruiting Site, Fairfax, Virginia, United States
Study of AVZO-021 in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorHR+/HER2- Breast CancerHR+, HER2-, Advanced Breast CancerCCNE1 AmplificationEpithelial Ovarian CancerPrimary Peritoneal CancerFallopian Tube CancerEndometrial CancerTNBC - Triple-Negative Breast Cancer
- Interventions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Avenzo Therapeutics, Inc.
- Target Recruit Count
- 430
- Registration Number
- NCT05867251
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States